SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation.


Journal

Acta medica academica
ISSN: 1840-2879
Titre abrégé: Acta Med Acad
Pays: Bosnia and Herzegovina
ID NLM: 101587903

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 04 02 2023
accepted: 13 04 2023
medline: 19 6 2023
pubmed: 16 6 2023
entrez: 16 6 2023
Statut: ppublish

Résumé

Patients diagnosed with hematologic malignancies are at increased risk for severe SARS-CoV-2 infection. We evaluated the serological IgG response following two doses of the SARS-CoV-2 vaccine in patients with hematologic malignancies. Patients treated at UT Southwestern Medical Center with a diagnosis of a myeloid or lymphoid neoplasm were included. SARS-CoV-2 vaccination response was defined as a positive quantifiable spike IgG antibody titer. Sixty patients were included in the study and 60% were diagnosed with a myeloid neoplasm. The majority (85%) of the patients with a myeloid malignancy and 50% of the patients with a lymphoid malignancy mounted a serological response after receiving two doses of the vaccine. Vaccination should be offered irrespective of ongoing treatment or active disease. Findings require validation in a larger cohort of patients.

Identifiants

pubmed: 37326395
pii: ama2006-124.399
doi: 10.5644/ama2006-124.399
pmc: PMC10316070
doi:

Substances chimiques

COVID-19 Vaccines 0
Immunoglobulin G 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

30-36

Informations de copyright

Copyright © Hoff et al. This article is available under a Creative Commons License (Attribution 4.0 International).

Références

Blood Adv. 2020 Dec 8;4(23):5966-5975
pubmed: 33278301
Blood. 2020 Sep 3;136(10):1134-1143
pubmed: 32688395
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Ann Hematol. 2022 Apr;101(4):929-931
pubmed: 34302519
Acta Haematol. 2022;145(3):257-266
pubmed: 35220303
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
Blood. 2020 Dec 17;136(25):2881-2892
pubmed: 33113551
N Engl J Med. 2021 Apr 22;384(16):1578
pubmed: 33596351
Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2
pubmed: 34133951
Ann Hematol. 2022 Aug;101(8):1825-1834
pubmed: 35597847
Br J Haematol. 2022 Jun;197(6):691-696
pubmed: 35226358
Blood. 2022 Jul 21;140(3):236-252
pubmed: 35544585
J Clin Microbiol. 2021 Jun 18;59(7):e0038821
pubmed: 33827901
Blood Adv. 2022 Apr 12;6(7):2014-2034
pubmed: 34852173
Cancer Cell. 2021 Aug 9;39(8):1031-1033
pubmed: 34331856

Auteurs

Fieke W Hoff (FW)

Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.

Suleyman Y Goksu (SY)

Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.

Naveen Premnath (N)

Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.

Prapti A Patel (PA)

Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.

Ruth Ikpefan (R)

Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.

Gurbakhash Kaur (G)

Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.

Madhuri Vusirikala (M)

Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.

Taha Bat (T)

Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.

Weina Chen (W)

Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX.

Praveen Ramakrishnan Geethakumari (PR)

Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.

Larry D Anderson (LD)

Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.

Farrukh T Awan (FT)

Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.

Robert H Collins (RH)

Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.

Olga K Weinberg (OK)

Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX.

Alagarraju Muthukumar (A)

Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX.

Stephen S Chung (SS)

Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.

Yazan F Madanat (YF)

Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA. yazan.madanat@utsouthwestern.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH